Ignite Creation Date:
2024-05-06 @ 12:23 PM
Last Modification Date:
2024-10-26 @ 12:58 PM
Study NCT ID:
NCT03745196
Status:
TERMINATED
Last Update Posted:
2020-06-12
First Post:
2018-10-24
Brief Title:
The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
Sponsor:
Pulmocide Ltd
Organization:
Pulmocide Ltd
Study Overview
Official Title:
A Double-blind Placebo-controlled Study to Assess the Effects of Inhaled PC945 in the Treatment of Culture-positive Aspergillus or Candida Fungal Bronchitis in Subjects With Moderate to Severe Asthma or Other Chronic Respiratory Diseases
Status:
TERMINATED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study is being terminated early as a result of the coronavirus COVID-19 outbreak
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study tests the effects of an experimental drug PC945 in people with asthma or other chronic respiratory diseases whose lungs are infected by Aspergillus fungi and Candida yeasts
PC945 may be useful in treating patients infected with Aspergillus as unlike the usual treatments it is inhaled into the lung and has been designed to stay there and treat the infection Participants will continue to receive their usual treatment for their chronic respiratory disease Half of the participants will receive PC945 and half will receive a placebo The amount of fungus and yeast in the patients phlegm will be measured over the course of the study The study will take place at multiple sites in UK and will include approximately 46 participants The maximum study duration will be about 16 weeks
PC945 may be useful in treating patients infected with Aspergillus as unlike the usual treatments it is inhaled into the lung and has been designed to stay there and treat the infection Participants will continue to receive their usual treatment for their chronic respiratory disease Half of the participants will receive PC945 and half will receive a placebo The amount of fungus and yeast in the patients phlegm will be measured over the course of the study The study will take place at multiple sites in UK and will include approximately 46 participants The maximum study duration will be about 16 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-000244-26 | EUDRACT_NUMBER | None | None |